SLU-PP-332 (SLU-PP-332 (ERR Agonist))
An experimental small-molecule "exercise mimetic" that activates estrogen-related receptors (ERRs). In animal studies it increased energy expenditure and endurance and reduced fat gain without changes in food intake or activity, by pushing cells toward fat-burning metabolism.
How it works
A pan-ERR (estrogen-related receptor alpha/beta/gamma) agonist. ERRs are master regulators of mitochondrial biogenesis and oxidative metabolism, so activation upregulates fat oxidation and the genetic program normally triggered by endurance exercise.
Key facts
- Molecular weight: ~426 Da (small molecule, not a peptide)
- Half-life: Not well characterized in humans
- Bioavailability: Studied via injection in animals; oral activity under investigation
- Storage: Store per supplier guidance; small molecules are often stable refrigerated and protected from light.
Dosing overview
- Typical dose: No established human dose
- Frequency: Unknown
- Duration: Unknown
- Route: Injection (preclinical)
Protocol notes
- Human dosing is not established. All current data are from rodent studies.
- Animal work used intraperitoneal injection over short study windows.
- Treat any human use as purely experimental with unknown safety.
Reported benefits
- Increases mitochondrial fat-burning (preclinical)
- Improved endurance in animals
- Reduced fat gain without appetite change (animals)
- Acts as an "exercise mimetic"
Possible side effects
- Human safety unknown
- No human side-effect data
- Potential cardiac/metabolic effects of broad ERR activation are unstudied in people
Research
- An ERR agonist that mimics aspects of exercise (2023): In mice, SLU-PP-332 boosted oxidative metabolism, increased running capacity, and limited diet-induced fat gain.
Community reviews of SLU-PP-332
- careful_claire rated it 5/5 - Genuinely effective after 3 months: Been using SLU-PP-332 for about 3 months and the results are clear. Not overnight dramatic, but a steady, consistent improvement that became undeniable by the end of the first month. The mechanism makes sense based on what I have read in the literature, and my subjective experience matches the expected timeline. Benefits built gradually and plateaued at a good level. Side effects were minimal to none at the dose I used. Followed proper protocols for sourcing, storage, and administration. Would recommend to others who have done their research and have realistic expectations.
- stack_logic_lisa rated it 5/5 - Noticed clear benefits within weeks: Added SLU-PP-332 to my protocol about 3 weeks ago and it has earned its place. The benefits became noticeable around week 2-3 and have been consistent since. What I appreciate about this compound is the predictability. It does what the research suggests it should do, at roughly the timeline you would expect. No surprises, no dramatic swings, just steady improvement. No notable side effects to report at my dose. Sourcing is always the challenge with research compounds, insist on third-party testing. Storage and reconstitution per standard protocols. Plan to continue.
- morning_pin_maya rated it 5/5 - Worth adding to the protocol: SLU-PP-332 has been a worthwhile addition. I am data-driven and tracked relevant markers before, during, and after. The improvement is measurable and correlates with the intervention timeline. What sets this apart from some compounds I have tried is the consistency. Benefits did not fluctuate wildly or disappear. They built up and maintained. That gives me confidence in the mechanism. Tolerance has been excellent. Nothing in my bloodwork or subjective experience raised any flags. This is the kind of compound that does its job quietly without causing problems. Exactly what you want.
Compare SLU-PP-332
Community discussions about SLU-PP-332
- Trying SLU-PP-332 as an “exercise mimetic” – my first 4‑week run - 4 comments
- Injection site irritation and unexpected heart rate spikes with SLU-PP-332 - 4 comments
- Ask the community about SLU-PP-332
Research and educational reference only. Not medical advice.